Benidipine is a dihydropyridine calcium channel blocker for the treatment of high blood pressure (hypertension). It is a triple L-, T-, and N-type calcium channel blocker. It is reno- and cardioprotective. It was patented in 1981 and approved for medical use in 1991.

Dosing

Benidipine is dosed as 2–8 mg once daily.

Mechanism

Benidipine is a calcium channel blocker. Benidipine has additionally been found to act as an antagonist of the

mineralocorticoid receptor The mineralocorticoid receptor (or MR, MLR, MCR), also known as the aldosterone receptor or nuclear receptor subfamily 3, group C, member 2, (NR3C2) is a protein that in humans is encoded by the ''NR3C2'' gene that is located on chromosome 4q31 ...

, or as an

antimineralocorticoid An antimineralocorticoid, also known as a mineralocorticoid receptor antagonist (MRA or MCRA) or aldosterone antagonist, is a diuretic drug which antagonizes the action of aldosterone at mineralocorticoid receptors. This group of drugs is often ...

Names

Other names include Benidipinum or benidipine hydrochloride. Benidipine is sold as Coniel by Kyowa Hakko Kogyo. Benidipine is initially licensed for use in Japan and selected

Southeast Asian Southeast Asia, also spelled South East Asia and South-East Asia, and also known as Southeastern Asia, South-eastern Asia or SEA, is the geographical United Nations geoscheme for Asia#South-eastern Asia, south-eastern region of Asia, consistin ...

countries and later in Turkey, where it is sold as 4 mg tablets.

References

{{Mineralocorticoidics Antimineralocorticoids Aldosterone synthase inhibitors Calcium channel blockers Carboxylate esters Dihydropyridines Methyl esters Nitrobenzenes Piperidines